Company profile for Mannkind

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available b...
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362
Telephone
Telephone
818.661.5000
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3196982/29517/en/MannKind-Announces-U-S-FDA-Accepts-for-Review-its-Supplemental-New-Drug-Application-sNDA-of-FUROSCIX-ReadyFlow-Autoinjector-for-the-Treatment-of-Edema-in-Adults-with-Chronic-Heart-.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/11/3185761/29517/en/MannKind-to-Present-at-the-Jefferies-Global-Healthcare-Conference.html

GLOBENEWSWIRE
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/10/3184523/29517/en/MannKind-Provides-Update-on-Phase-3-ICoN-1-Trial-of-Nebulized-Clofazimine-for-NTM-Lung-Disease.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3182687/29517/en/MannKind-Commemorates-Alfred-E-Mann-s-100th-Birthday-with-New-Scholarship-Program-Supporting-Young-Adults-Living-with-Diabetes.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176846/29517/en/MannKind-Corporation-to-Hold-2025-Third-Quarter-Financial-Results-Conference-Call-on-November-5-2025.html

GLOBENEWSWIRE
29 Oct 2025

ABOUT THIS PAGE

Contact Mannkind and get a quotation

Mannkind is a supplier offers 3 products (APIs, Excipients or Intermediates).

Find a price of Insulin bulk with DMF offered by Mannkind

Find a price of Treprostinil Sodium bulk with DMF offered by Mannkind

Find a price of Insulin bulk offered by Mannkind

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty